Partial hepatectomy versus interventional treatment in patients with hepatitis B virus-related hepatocellular carcinoma and clinically significant portal hypertension: a randomized comparative clinical trial

被引:0
作者
Yuan, Yichuan [1 ,2 ]
Peng, Hong [3 ]
He, Wei [1 ,2 ]
Zheng, Yun [1 ,2 ]
Qiu, Jiliang [1 ,2 ]
Chen, Bin [3 ]
Zou, Ruhai [4 ]
Wang, Chenwei [1 ,2 ]
Lau, Wan Yee [5 ]
Li, Binkui [1 ,2 ]
Yuan, Yunfei [1 ,2 ]
机构
[1] Sun Yat Sen Univ, Guangdong Prov Clin Res Ctr Canc, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Dept Liver Surg, Guangzhou, Guangdong, Peoples R China
[3] Sun Yat sen Univ, Affiliated Hosp 1, Ctr Hepatocellular Pancreatobiliary Surg, Guangzhou, Guangdong, Peoples R China
[4] Sun Yat sen Univ, Dept Ultrasound, Canc Ctr, Guangzhou, Guangdong, Peoples R China
[5] Chinese Univ Hong Kong, Fac Med, Hong Kong, Peoples R China
基金
中国国家自然科学基金;
关键词
hepatocellular carcinoma; portal hypertension; partial hepatectomy; interventional treatment; VENOUS-PRESSURE GRADIENT; LIVER RESECTION; CIRRHOTIC-PATIENTS; CONTRAINDICATION; ABLATION; OUTCOMES;
D O I
10.1002/cac2.12614
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:The widely accepted view that portal hypertension (PHT) is a con-traindication to hepatectomy for patients with hepatocellular carcinoma (HCC)is being increasingly challenged. The long-term survival outcomes and safetyof partial hepatectomy versus interventional treatment using ablation with orwithout pre-ablation transarterial chemoembolization (TACE) in patients withHBV-related HCC within the Milan criteria and with clinically significant PHTwere compared in this study. Methods:This open-label randomized clinical trial was conducted on consecu-tive patients with clinically PHT and hepatitis B virus (HBV)-related HCC withtumors which were within the Milan criteria. These patients were randomized1:1 to receive either partial hepatectomy or interventional treatment betweenDecember 2012 and June 2018. The primary endpoint was overall survival (OS);secondary endpoints included recurrence-free survival (RFS) and therapeuticsafety. Results:Each of the 2 groups had 80 patients. The 1-, 3- and 5-year OS ratesin the partial hepatectomy group and the interventional treatment group were95.0%, 86.2%, 69.5% versus 93.8%, 77.5%, 64.9%, respectively (P=0.325). Thecorresponding RFS rates were 78.8%, 55.0%, 46.2% versus 71.3%, 52.5%, 45.0%,respectively (P=0.783). The partial hepatectomy group had a higher compli-cation rate compared to the interventional group (67.5% vs. 20%,P<0.001).However, the differences were mainly in Clavien-Dindo Grade I complications(P<0.001), while not significant in Grade II/III/IV/V (AllP>0.05). Conclusions:This study shows that partial hepatectomy treatmentdid not meetprespecified significance for improved OS and RFS compared to interventionaltreatment for patients with HBV-related HCC within the Milan criteria and withclinically significant PHT. However, partial hepatectomy is still a safe procedureand should be considered as a treatment option rather than a contraindication.
引用
收藏
页码:1337 / 1349
页数:13
相关论文
共 34 条
  • [1] Bayraktar Y, 1996, AM J GASTROENTEROL, V91, P554
  • [2] Beighiti J, 2002, HEPATO-GASTROENTEROL, V49, P41
  • [3] Portal Hypertension and the Outcome of Surgery for Hepatocellular Carcinoma in Compensated Cirrhosis: A Systematic Review and Meta-analysis
    Berzigotti, Annalisa
    Reig, Maria
    Abraldes, Juan G.
    Bosch, Jaime
    Bruix, Jordi
    [J]. HEPATOLOGY, 2015, 61 (02) : 526 - 536
  • [4] Hepatic venous pressure gradient in the assessment of portal hypertension before liver resection in patients with cirrhosis
    Boleslawski, E.
    Petrovai, G.
    Truant, S.
    Dharancy, S.
    Duhamel, A.
    Salleron, J.
    Deltenre, P.
    Lebuffe, G.
    Mathurin, P.
    Pruvot, F. R.
    [J]. BRITISH JOURNAL OF SURGERY, 2012, 99 (06) : 855 - 863
  • [5] Surgical resection of hepatocellular carcinoma in cirrhotic patients: Prognostic value of preoperative portal pressure
    Bruix, J
    Castells, A
    Bosch, J
    Feu, F
    Fuster, J
    GarciaPagan, JC
    Visa, J
    Bru, C
    Rodes, J
    [J]. GASTROENTEROLOGY, 1996, 111 (04) : 1018 - 1022
  • [6] Portal hypertension:: Contraindication to liver surgery?
    Capussotti, Lorenzo
    Ferrero, Alessandro
    Vigano, Luca
    Muratore, Andrea
    Polastri, Roberto
    Bouzari, Hedayat
    [J]. WORLD JOURNAL OF SURGERY, 2006, 30 (06) : 992 - 999
  • [7] Chinese Society of Spleen and Portal Hypertension Surgery Chinese Society of Surgery Chinese Medical Association, 2022, Zhonghua Wai Ke Za Zhi, V60, P310, DOI 10.3760/cma.j.cn112139-20220105-00009
  • [8] The Clavien-Dindo Classification of Surgical Complications Five-Year Experience
    Clavien, Pierre A.
    Barkun, Jeffrey
    de Oliveira, Michelle L.
    Vauthey, Jean Nicolas
    Dindo, Daniel
    Schulick, Richard D.
    de Santibanes, Eduardo
    Pekolj, Juan
    Slankamenac, Ksenija
    Bassi, Claudio
    Graf, Rolf
    Vonlanthen, Rene
    Padbury, Robert
    Cameron, John L.
    Makuuchi, Masatoshi
    [J]. ANNALS OF SURGERY, 2009, 250 (02) : 187 - 196
  • [9] Is Portal Hypertension a Contraindication to Hepatic Resection?
    Cucchetti, Alessandro
    Ercolani, Giorgio
    Vivarelli, Marco
    Cescon, Matteo
    Ravaioli, Matteo
    Ramacciato, Giovanni
    Grazi, Gian Luca
    Pinna, Antonio Daniele
    [J]. ANNALS OF SURGERY, 2009, 250 (06) : 922 - 928
  • [10] European Assoc Study Liver, 2012, EUR J CANCER, V48, P599, DOI [10.1016/j.ejca.2011.12.021, 10.1016/j.jhep.2011.12.001]